Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5876MR)

This product GTTS-WQ5876MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5876MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4244MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ11503MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ557MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ5675MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ15938MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ3989MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ6598MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ15994MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00521505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW